Pharmacological Interventions Effective in Improving Exercise Capacity in Heart Failure

Area of Science:

• Cardiology
• Pharmacology
• Exercise Physiology

Background:

• Heart failure (HF) significantly limits exercise capacity, impacting patient quality of life (QOL) and prognosis.
• Exercise intolerance is a primary characteristic of heart failure, leading to reduced physical function.

Purpose of the Study:

• To review current pharmacological interventions for improving exercise capacity in patients with heart failure.
• To summarize evidence on drugs that enhance functional capacity in HF.

Main Methods:

• Systematic review of pharmacological interventions.
• Analysis of European Society of Cardiology (ESC) guidelines for HF management.
• Evaluation of studies demonstrating effects on exercise capacity and QOL.

Main Results:

• Ivabradine, trimetazidine, and intravenous iron are identified as key pharmacological agents.
• These interventions are consistently shown to improve functional capacity in HF patients.
• Positive effects on HF symptoms, physical performance, and QOL are documented.

Conclusions:

• Specific pharmacological treatments offer a viable strategy to enhance exercise capacity in heart failure.
• Ivabradine, trimetazidine, and intravenous iron represent important therapeutic options for improving HF patient outcomes.
• These drugs contribute to better symptom management, physical function, and overall QOL in heart failure.